Los participantes del ensayo clnico que tomaron tirzepatida, el medicamento vendido como Zepbound, perdieron 22,8 kilogramos (50 libras) en promedio durante 72 semanas, mientras que aquellos que tomaron semaglutida, o Wegovy, perdieron alrededor de 15 kilos (33 libras), de acuerdo con el estudio financiado por Lilly y que fue publicado en el New England Journal of Medicine
Thus, GLP-1-based therapies could potentially target both diabetes and cardiovascular disease
Alternatively, a patient who is tender on palpation and yet negative on all three of these tests is unlikely to have the condition
they are a sign that the body is working through a backlog of cellular waste
Nakahata, Y
Furthermore, increased fiber consumption is correlated with improvements in lipid profiles, glycemic regulation, and intestinal function